Companies / Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc.
TERNCIK 1831363FOSTER CITY, CA
Financials · FY2022
Ownership
115.5M shares outstanding · as of Apr 17, 2026
Ownership
| Insiders | 0.43% | 497,379 |
| 10%+ / strategic | 2.73% | 3,150,000 |
| Institutions | 112.01% | 129,390,111 |
| Public float | 0.00% | 0 |
Reported holdings exceed shares outstanding — public float shown as 0; some positions may overlap or lag.
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 9
View all →| Insider | % of shares | Shares |
|---|---|---|
Burroughs Amy L.CEOChief Executive Officer · Director | 0.25% | 288,976 |
Kuriakose EmilChief Medical Officer | 0.09% | 106,615 |
Gengos AndrewChief Financial Officer | 0.09% | 101,788 |
Azelby RobertDirector | — | — |
Fellows David aDirector | — | — |
Kindler Jeffrey BDirector | — | — |
Quigley Jill M.Director | — | — |
Tripuraneni RadhikaDirector | — | — |
Turner Heather DDirector | — | — |
Institutional holders 281
View all →| Holder | Value | % of shares |
|---|---|---|
| $331.05M | 7.09% | |
| $321.00M | 6.88% | |
| $223.17M | 4.78% | |
| $216.02M | 4.63% | |
| $181.80M | 3.90% | |
| $175.74M | 3.77% | |
| $158.77M | 2.61% | |
| $155.52M | 2.55% | |
| $146.53M | 2.41% | |
| $127.93M | 2.74% |
Activity
Mar 31, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q2 2026 as of | BlackRock, Inc. 13F manager | Exit | Common stock | $-331.05M | -8.2M -100.00% | 0 | high |
| Q1 2026 as of | Adage Capital Partners Gp, L.L.C. 13F manager | Trim | Common stock | $-180.58M | -3.4M -61.72% | 2,124,817 1.84% of shares | high |
| Q1 2026 as of | Hbk Investments L P 13F manager | New | Common stock | $155.52M | +3.0M | 2,950,000 2.55% of shares | high |
| Q1 2026 as of | Millennium Management LLC 13F manager | Add | Common stock | $106.72M | +2.0M +205.03% | 3,011,558 2.61% of shares | high |
| Q1 2026 as of | Janus Henderson Group PLC 13F manager | Trim | Common stock | $-100.68M | -1.9M -56.50% | 1,470,057 1.27% of shares | high |
| Q1 2026 as of | Balyasny Asset Management L.P. 13F manager | Add | Common stock | $99.51M | +1.9M +211.63% | 2,779,445 2.41% of shares | high |
| Q1 2026 as of | Orbimed Advisors LLC 13F manager | Exit | Common stock | $-86.99M | -2.2M -100.00% | 0 | high |
| Q2 2026 as of | State Street Corporation 13F manager | Exit | Common stock | $-71.75M | -1.8M -100.00% | 0 | high |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Vanguard Group Inc | Passive13G/A | — |
| Adage Capital Management, L.P. | Passive13G | — |
| Soleus Capital Master Fund, L.P. | Passive13G/A | — |
| Deep Track Capital, LP | Passive13G/A | — |
| Vivo Opportunity Fund Holdings, L.P. | Passive13G/A | — |
| Commodore Capital LP | Passive13G/A | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| TERN | — | 880881107 |